As the year concludes, Joey Bose reflects on gratitude towards investors, the Cytonics community, and the dedicated team. He emphasizes the importance of long-term commitment and support in their progress. Looking ahead to 2026, he encourages everyone to cherish time with loved ones and appreciate their contributions.
Some individuals inherit a genetic risk for osteoarthritis, potentially experiencing severe symptoms by their 40s or 50s. Early identification and treatment with alpha-2-macroglobulin (A2M) may preserve joint health and enhance quality of life. Development of CYT-108 aims to target the root cause of osteoarthritis, rather than just alleviate pain.
Joey Bose, our CEO and President, breaks down why researchers have called A2M the 'physiological guardian.' A2M, or alpha-2-macroglobulin, is a natural protein found in your bloodstream that acts like a bodyguard against inflammation and joint destruction. It works as a broad-spectrum protease inhibitor and also sequesters cytokines – the same inflammatory signals you heard…
The message emphasizes gratitude towards patients and investors who contribute to Cytonics’ mission. Highlighting milestones like treating over 10,000 patients and issuing 25 patents, it reinforces that Cytonics is community-driven and not just a typical biotech firm. The team appreciates all stakeholders and encourages further investment.
Cytonics has developed CYT-108, a refined version of the naturally occurring protein Alpha-2-Macroglobulin (A2M), to combat osteoarthritis. By optimizing A2M for enhanced protease inhibition, the precision-engineered biologic minimizes side effects and maximizes therapeutic potential. It’s backed by extensive scientific validation and patented for patient safety and efficacy.
The journey of developing a cartilage-protecting therapy began with a hypothesis about the A2M protein’s potential. Initial experiments showed A2M could significantly reduce cartilage destruction caused by osteoarthritis. This led to the creation of APIC™ and the more advanced CYT-108, which demonstrated remarkable efficacy in preclinical trials, paving the way for human clinical trials.
Cytonics has released a video featuring CEO Joey Bose, explaining how their therapy CYT-108 challenges Big Pharma by targeting osteoarthritis’s root causes, rather than just symptoms. The video discusses past successes with APIC, the science behind their approach, and future strategies. Viewers are encouraged to support the company as potential shareholders.
Cytonics has completed its first-in-human trial for CYT-108, a recombinant protease inhibitor for knee osteoarthritis. The 22-patient Phase 1 study focused on safety and efficacy, providing data for an FDA IND application and Phase 2 protocol. This milestone boosts prospects for a disease-modifying therapy and enhances shareholder value.
Cytonics Corporation has received US Patent No. US 12,195,521 B2 for its engineered A2M variant, CYT-108. This patent enhances its competitive position by expanding therapeutic applications and securing exclusivity for two decades. It strengthens barriers to entry, increases licensing opportunities, and supports funding initiatives for future product development.
